Short Bites: Effects of Antiretroviral Therapy (ART) on Oral Lesions

Topic: 
Publish Date: 
Wednesday, December 13, 2017

A recent study that was conducted among 1200 HIV patient of whom 600 each belonged to with ART and without ART and the occurrence of oral candidiasis and oral hairy leukoplakia. This study shows that oral candidiasis and leukoplakia was less among patients on ART as well as a decrease in the number of opportunistic infections.[1]  This is important as oral manifestations might serve as an important marker for monitoring restoration of immune function and ART failure.

Short Bites: Xerostomia in Patients Living with HIV

Topic: 
Publish Date: 
Tuesday, November 7, 2017

It is estimated that 1.1 million people in the United States are living with HIV. Of those, 1 in 7 do not know they are infected.[1] The number of new HIV diagnoses fell 19% from 2005 to 2014.[1] Because HIV testing rates have remained stable or increased in recent years, this decrease in diagnoses suggests a true decline in new infections. The statistics in the Southern United States are not as promising.

Short Bites: One in Nine American Men are Infected with Oral HPV

Topic: 
Publish Date: 
Tuesday, October 31, 2017

According to a new study published in the Journal Annals of Internal Medicine, one in nine American men is infected with the oral form of the human papillomavirus (HPV). Nationwide, rates of oral HPV infection are 11.5% of men vs. 3.2% women. HPV 16, the most common type of high-risk HPV and known to contribute to head and neck cancers, was six times higher in men than women.

Giving New Life to New Jersey Syringe Access Programs

Publish Date: 
Monday, October 16, 2017

I had the honor to help develop the first legal syringe access program (SAP) in Atlantic City, NJ, almost 10 years ago. In 2006, the New Jersey legislature passed the Blood-Borne Disease Harm Reduction Act, which allowed for the establishment of up to six pilot SAPs in NJ; however, approval from each selected city’s government was required before opening.

Doravirine in Initial Therapy: DRIVE-AHEAD Study

Publish Date: 
Tuesday, October 3, 2017

Doravirine (DOR) is an investigational NNRTI that currently is being developed in a coformulation with TDF and FTC. A Phase 3 comparison of DOR + 2 NRTIs (87% of study subjects were given TDF/FTC) and DRV/r + 2 NRTIs in initial therapy was presented at CROI earlier this year (DRIVE-FORWARD); the DOR arm was found to be noninferior to the DRV arm (see CROI 2017: Doravirine Noninferior to Darunavir + Ritonavir in Initial Treatment).

On the Way: The First Protease Inhibitor-Based Single-Tablet Regimen

Publish Date: 
Thursday, September 28, 2017

The EMERALD Study is a Phase 3 randomized (2:1), open-label, noninferiority study examining the strategy of switching patients with suppressed HIV RNA on a regimen consisting of a boosted protease inhibitor plus tenofovir disoproxil fumarate (TDF)/emtricitabine to an investigational single-tablet regimen containing<--break-> darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg (D/C/F/TAF).

Bictegravir in Initial Therapy

Publish Date: 
Thursday, September 28, 2017

These studies demonstrate that coformulated BIC/TAF/FTC is noninferior to two gold-standard regimens comprised of DTG with 2-NRTI backbones, and in fact suggest that BIC/TAF/FTC is better tolerated than the coformulation DTG/ABC/3TC. Importantly, rates of virologic suppression were very high with all regimens, and no resistance mutations were seen in the rare cases of virologic failure.

Recap: 17th Ryan White HIV/AIDS Program Clinical Care Conference

Publish Date: 
Thursday, August 31, 2017

Highlights from Laura W. Cheever, MD, ScM, HRSA HIV/AIDS Bureau Associate Administrator and Conference Co-Chair. "It’s a great balance between state-of-the-art treatment and science and pragmatic things that Ryan White HIV/AIDS Program providers struggle with and need assistance with."

Pages

Subscribe to Sharespot RSS feed